Most Awaited Q3 Sale is back. Upto 30% discount on every report.

Ovulation Disorder Diagnosis Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2022 October 12
SKU : CD803
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Ovulation Disorder Diagnosis Market is segmented By Ovulation Disorders (Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumours, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome, Others), By Diagnosis (Laboratory Testing of Hormones, CT Scan and MRI Scan of The Pituitary Gland and Hypothalamus, Ovarian Biopsy and others), By End-users (Hospitals, Gynaecological Clinics, and others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis,  2022-2029


Ovulation Disorder Diagnosis Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.8% during the forecast period (2022-2029).  

Ovulation Disorder Diagnosis Market



Market CAGR


Segments Covered

By Ovulation Disorders, By Diagnosis, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Ovulation disorders are the main source of infertility in women or girls. Ovulation disorders are disturbances in the production of an egg during a woman’s menstrual cycle. The disorders often occur due to hypothalamic dysfunction, premature ovarian failure and polycystic ovary syndrome.

Market Dynamics

The ovulation disorder diagnosis market growth is driven by the rising adoption of planned pregnancies, a decrease in fertility rate along with increasing awareness of different ovulation disorders among the public

The prevalence of polycystic ovary syndrome (PCOS) in patients with type 2 diabetes is expected to drive the market growth   

Polycystic ovary syndrome (PCOS) is a common metabolic and endocrine reproductive disease associated with cardiovascular, metabolic, and psychological factors affecting around  7% of women globally. As per the article published in Frontiers in Endocrinology in August 2022, Diabetes mellitus (DM) is a global public health concern. Around 537 million adults (20-79 years old) worldwide have developed DM in 2021, mostly in the younger age group. Now, more patients are developing type 2 DM (T2DM) at a younger age, and women with T2DM are affected more often during the reproductive period. Reproductive dysfunction in women patients with T2DM is cautiously increasing. Compared with patients without T2DM, patients with T2DM show more clinical changes, such as menstrual disorders and polycystic ovaries. This may be associated with the rise in cellular androgen levels induced by the cooperation of luteinizing hormone and insulin.

In addition, PCOS results from ovarian granulosa cells' stimulation by endogenous insulin resistance in type 2 diabetes and hyperinsulinem, which promote the growth and number of small follicles. PCOS and T2DM have biochemical, clinical, and metabolic characteristics. There is also a high overlap rate between patients with PCOS or T2DM. T2DM involved by PCOS may result in evaluative injuries to the reproductive system. The more patients with PCOS drive the market.

The lack of awareness in public will hamper the growth of the market

However, advanced knowledge gaps among health professionals and patients contribute to diagnostic delays and variation in care. In addition, a dearth of evidence-based, accessible information for affected women leads to dissatisfaction. Many women are unaware of ovulation, which disorders diagnosis information and causes infertility and is linked with various health risks.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global ovulation disorder diagnosis market. As per the article published in BMC Medicine in July 2020, in women of reproductive age, polycystic ovary syndrome (PCOS) constitutes the most frequent endocrine disorder, with a prevalence that may reach or even exceed 10–15%. The more chances are there of getting infected from COVID-19. On the other hand, many patients faced difficulty receiving their regular treatments during the pandemic due to transportation restrictions and lockdowns. Many industries are locked down in the pandemic, which negatively impacts the market.

However, because the situation is reversing in the middle of 2022 rather than 2021, the patient can now receive treatment in the hospital. The market will also show good growth in the forecast period.

Segment Analysis

The polycystic ovarian syndrome segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)    

The polycystic ovarian syndrome segment is expected to boost the market over the period of the forecast. In some cases, a female doesn't make enough of the hormones required to ovulate. When ovulation doesn't happen, the ovaries develop many small cysts. These cysts generate hormones called androgens. Females with PCOS often have high levels of androgens. This results in more problems with a woman's menstrual cycle and can cause many symptoms of PCOS. If anyone has irregular periods and higher levels of androgen shown in blood tests, these women have PCOS. According to the Cleveland Clinic, PCOS is very common; up to 15% of women of reproductive age have it. Women not diagnosed and treated for PCOS may be at risk for developing conditions that raise the risk of cardiovascular disease, including obesity, high blood pressure, gestational diabetes, and high cholesterol. Therefore, diagnosing PCOS is important and increasing cases of PCOS lead to increasing demand for the diagnosis market. There's no single test specifically diagnosing polycystic ovary syndrome (PCOS). The healthcare professionals suggested a pelvic exam, blood tests, and ultrasound.

Geographical Analysis

North America region holds the largest market share of the global ovulation disorder diagnosis market

North America dominates the market for ovulation disorder diagnostics and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2022-2029) owing to advanced healthcare infrastructure and rising awareness in public regarding ovulation disorder diagnosis. According to the Centers for Disease Control and Prevention, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (as many as 5 million) of US women of reproductive age. The cases of PCOS and increasing health awareness in women drive the market in the North American region. In addition, the key players are adopting market strategies such as mergers and new launches of the product. For instance, in December 2021, Labcorp acquired the Toxikon Corporation, a contract research organization delivering best-in-class nonclinical testing services. Adding Toxikon to Labcorp Drug Development bolsters Labcorp’s strong nonclinical development portfolio.

Competitive Landscape

The ovulation disorder diagnosis market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Siemens Healthcare, GE Healthcare, Fujifilm Holdings, Swiss Precision Diagnostics, Toshiba Medical Systems Corporation, Carestream Health, Genova Diagnostics, Quest Diagnostics, LabCorp, and Esaote, among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the ovulation disorder diagnosis market globally.

For instance,

  • In July 2022, Canon Medical Systems USA Inc. acquired NXC Imaging, a medical imaging equipment distributor and service provider headquartered in Minneapolis, Minnesota.

Toshiba Medical Systems Corporation (TMSC)


TMSC is a company which is manufactured, sells, and provisions technical services for medical equipment, including diagnostic x-ray systems, medical x-ray CT systems, magnetic resonance imaging systems (MRI), computed tomography (CT) diagnostic ultrasound systems, radiation therapy systems, and others.

Treatment type Portfolio:

Computed Tomography: The system provides new clinical values such as functional diagnosis and dynamic observation apart from conventional morphological. Also able to provide 160 mm-wide coverage of 3D imaging in one rotation with 0.35 seconds, and it is patient-friendly medical care and requires less scanning time and exposure dose.

The global ovulation disorder diagnosis market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

Trending Topics

Bone Cancer Diagnosis Market

Diagnostic Imaging Equipment Market

Diagnostic Electrophysiology Catheters Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy
Request new version